BRPI0410867A - composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer - Google Patents

composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer

Info

Publication number
BRPI0410867A
BRPI0410867A BRPI0410867-1A BRPI0410867A BRPI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A
Authority
BR
Brazil
Prior art keywords
drug
agent
therapeutic
inhibitor
compound
Prior art date
Application number
BRPI0410867-1A
Other languages
English (en)
Inventor
Akira Masuda
Yoshitaka Satoh
Yuji Akiyama
Kan Saiga
Eriko Toyoda
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of BRPI0410867A publication Critical patent/BRPI0410867A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO, MEDICAMENTO, INIBIDOR DE APRESENTAçãO DE ANTìGENO, AGENTE IMUNOSSUPRESSOR, INIBIDORES DE PROLIFERAçãO DE LINFóCITOS, E DE CRESCIMENTO E MATURAçãO DE CéLULAS, AGENTE TERAPêUTICO OU PREVENTIVO, INDUTOR DE TOLERáNCIA IMUNOLóGICA, E, DROGA ANTI-CáNCER". Derivado de ¢1,2,4!triazolo¢1,5-a!pirimidina inédito da fórmula geral (1): (1) prodroga do mesmo ou um sal farmaceuticamente aceitável do mesmo, que apresenta uma atividade inibidora de apresentação de antígeno e é útil como um agente preventivo e/ou terapêutico para rejeição imunológica e/ou reação do enxerto contra hospedeiro em transplante de órgão/medula óssea, doença autoimune, doença alérgica e/ou doença inflamatória e também útil como uma droga anti-câncer ou como um indutor de tolerância imunológica para órgão transplantado/medula óssea transplantada.
BRPI0410867-1A 2003-06-03 2004-06-02 composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer BRPI0410867A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003157663 2003-06-03
PCT/JP2004/007623 WO2004108729A1 (ja) 2003-06-03 2004-06-02 ［１，２，４］トリアゾロ［１，５−a］ピリミジン−２−イルウレア誘導体とその用途

Publications (1)

Publication Number Publication Date
BRPI0410867A true BRPI0410867A (pt) 2006-07-04

Family

ID=33508397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410867-1A BRPI0410867A (pt) 2003-06-03 2004-06-02 composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer

Country Status (14)

Country Link
US (1) US7598244B2 (pt)
EP (1) EP1630165B1 (pt)
JP (1) JP4698419B2 (pt)
KR (1) KR101097479B1 (pt)
CN (1) CN1809570B (pt)
AT (1) ATE462705T1 (pt)
AU (1) AU2004245351B2 (pt)
BR (1) BRPI0410867A (pt)
CA (1) CA2526211C (pt)
DE (1) DE602004026298D1 (pt)
RU (1) RU2348636C2 (pt)
TW (1) TWI334868B (pt)
WO (1) WO2004108729A1 (pt)
ZA (1) ZA200509436B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005104895A (ja) * 2003-09-30 2005-04-21 Nippon Kayaku Co Ltd 光学活性なアミノアルコール化合物の製造法
JP4606015B2 (ja) * 2003-11-25 2011-01-05 日本化薬株式会社 ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体の新規医薬用途
KR20070047763A (ko) * 2004-07-20 2007-05-07 시에나 바이오테크 에스.피.에이. 알파7 니코틴성 아세틸콜린 수용체의 조절제 및 그의치료적 용도
WO2007098826A2 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
KR20080091829A (ko) * 2006-02-09 2008-10-14 엔존 파마슈티컬즈, 인코포레이티드 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
EP2277881A4 (en) * 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
CN102834506A (zh) * 2010-02-23 2012-12-19 日本化药株式会社 调节性树突细胞的制备方法
CA2848557A1 (en) * 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
KR102116107B1 (ko) 2013-12-30 2020-05-28 삼성디스플레이 주식회사 표시 장치
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
CN107073069B (zh) * 2014-08-18 2022-03-08 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
JP7092356B2 (ja) 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
EP3818053B1 (en) 2018-07-05 2023-03-29 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
JPH01270051A (ja) * 1988-04-22 1989-10-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
US5484760A (en) * 1990-12-31 1996-01-16 Monsanto Company Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides
US5201938A (en) * 1991-07-19 1993-04-13 Dowelanco N-pyrazolyl-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamide herbicides
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
JPH10206995A (ja) * 1997-01-21 1998-08-07 Konica Corp ハロゲン化銀写真感光材料
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
JP2001322933A (ja) * 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
AU9502601A (en) * 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant

Also Published As

Publication number Publication date
CN1809570A (zh) 2006-07-26
EP1630165A1 (en) 2006-03-01
EP1630165A4 (en) 2007-11-21
KR101097479B1 (ko) 2011-12-22
US20070010515A1 (en) 2007-01-11
AU2004245351B2 (en) 2009-04-02
DE602004026298D1 (de) 2010-05-12
RU2005137706A (ru) 2006-06-10
JP4698419B2 (ja) 2011-06-08
EP1630165B1 (en) 2010-03-31
RU2348636C2 (ru) 2009-03-10
JPWO2004108729A1 (ja) 2006-07-20
CA2526211A1 (en) 2004-12-16
WO2004108729A1 (ja) 2004-12-16
CA2526211C (en) 2011-12-20
ATE462705T1 (de) 2010-04-15
US7598244B2 (en) 2009-10-06
AU2004245351A1 (en) 2004-12-16
KR20060026033A (ko) 2006-03-22
TWI334868B (en) 2010-12-21
TW200508238A (en) 2005-03-01
CN1809570B (zh) 2011-06-22
ZA200509436B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
BRPI0410867A (pt) composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer
Zhao et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model
RU2220977C2 (ru) Гетероциклы в качестве ингибиторов адгезии лейкоцитов и vla-4-антагонистов
DE602005016718D1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
CY1117672T1 (el) Αναστολεις της ανθρωπινης δελτα φωσφατιδυλ-ινοσιτολ-3-κινασης
DE69920732D1 (de) Bicyclische stickstoffheteroaryl verbindungen
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
CY1118493T1 (el) Κιναζολινονες ως αναστολεις της ανθρωπινης 3-κινασης δελτα της φωσφατιδυλινοσιτολης
EA200601850A1 (ru) 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
ATE277044T1 (de) Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
EP2280012A3 (en) Pyrrolo[2,1-f][1,2,4]triazine derivatives as kinase inhibitors
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
BR0007447A (pt) 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas substituìdas, composições farmacêuticas e métodos
NZ701440A (en) Pyrazole derivatives as jak inhibitors
MY143466A (en) Inhibitors of tyrosine kinases
EP1070710A3 (en) Dithiolan derivatives, their preparation and their therapeutic effect
RU2008123839A (ru) Соединение оксазола и фармацевтическая композиция
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
BRPI0513888A (pt) composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico
TW200420562A (en) Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
RU2006128788A (ru) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.